Literature DB >> 21737024

Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights.

Christopher J Rhodes1, Luke S Howard, Mark Busbridge, Damien Ashby, Eumorfia Kondili, J Simon R Gibbs, John Wharton, Martin R Wilkins.   

Abstract

OBJECTIVES: This study sought to understand the prevalence and clinical relevance of iron deficiency in patients with idiopathic pulmonary arterial hypertension (IPAH).
BACKGROUND: Iron availability influences the pulmonary vascular response to hypoxia in humans and may be significant in the pathogenesis of IPAH.
METHODS: Iron deficiency, defined by raised levels of soluble transferrin receptor (sTfR), was investigated in 98 patients with IPAH. Hepcidin and erythropoietin (EPO) levels were also measured. The effect of bone morphogenetic protein (BMP) receptor knockdown on BMP-6-stimulated hepcidin production was assessed in human hepatoma HepG2 cells. Relationships between sTfR and exercise capacity, functional class, and all-cause mortality were analyzed.
RESULTS: Circulating sTfR levels were raised in 63% of IPAH patients, indicating significant iron deficiency. Consistent with this, iron, ferritin, and transferrin saturation levels were reduced and red cell distribution width increased, without overt anemia. Hepcidin correlated inversely with sTfR and positively with increasing ferritin. Hepcidin was inappropriately raised in IPAH independent of the inflammatory marker interleukin-6. EPO levels were also raised and correlated inversely with hepcidin. BMP receptor-type 2 (BMPR2) knockdown in HepG2 cells increased BMP-6-stimulated hepcidin expression. sTfR increased with World Health Organization functional class (p < 0.05), correlated negatively with exercise capacity (p = 0.027), and values >28.1 nmol/l independently predicted survival (p = 0.011).
CONCLUSIONS: Iron deficiency is common in IPAH patients and associated with disease severity and poor clinical outcome. Inappropriately raised hepcidin levels, which impair iron absorption from the gut, may be a factor.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737024     DOI: 10.1016/j.jacc.2011.02.057

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  80 in total

1.  Iron Metabolism and Vascular Remodeling: Novel Insights Provided by Transferrin-1 Receptor Depletion in Mice With Pulmonary Hypertension.

Authors:  Michael S Wolin; Dhara Patel; Raed Alhawaj; Sachin A Gupte; Dong Sun
Journal:  Am J Hypertens       Date:  2015-11-04       Impact factor: 2.689

2.  Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome.

Authors:  Christopher J Rhodes; Pablo Otero-Núñez; John Wharton; Emilia M Swietlik; Sokratis Kariotis; Lars Harbaum; Mark J Dunning; Jason M Elinoff; Niamh Errington; A A Roger Thompson; James Iremonger; J Gerry Coghlan; Paul A Corris; Luke S Howard; David G Kiely; Colin Church; Joanna Pepke-Zaba; Mark Toshner; Stephen J Wort; Ankit A Desai; Marc Humbert; William C Nichols; Laura Southgate; David-Alexandre Trégouët; Richard C Trembath; Inga Prokopenko; Stefan Gräf; Nicholas W Morrell; Dennis Wang; Allan Lawrie; Martin R Wilkins
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

3.  Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis.

Authors:  Takao Yogo; Kiyoshi Okazuka; Junichiro Nashimoto; Yui Uto; Kota Sato; Kanji Miyazaki; Mizuki Ogura; Yumiko Yoshiki; Yu Abe; Nobuhiro Tsukada; Tadao Ishida; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2019-06-24       Impact factor: 2.490

Review 4.  The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.

Authors:  Jeffrey C Robinson; Brian B Graham; Tracey C Rouault; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2014-12       Impact factor: 6.914

Review 5.  Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options.

Authors:  Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2014-12-06       Impact factor: 5.460

6.  Ironing out pulmonary arterial hypertension.

Authors:  Jodie L Babitt
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-06       Impact factor: 11.205

7.  Iron chelation inhibits the development of pulmonary vascular remodeling.

Authors:  Chi-Ming Wong; Ioana R Preston; Nicholas S Hill; Yuichiro J Suzuki
Journal:  Free Radic Biol Med       Date:  2012-08-25       Impact factor: 7.376

8.  Hemodynamic response to treatment of iron deficiency anemia in pulmonary arterial hypertension: longitudinal insights from an implantable hemodynamic monitor.

Authors:  Muddassir Mehmood; Richa Agarwal; Amresh Raina; Priscilla Correa-Jaque; Raymond L Benza
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 9.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

10.  The Therapeutic Effects of Human Mesenchymal Stem Cells Primed with Sphingosine-1 Phosphate on Pulmonary Artery Hypertension.

Authors:  Hyunsook Kang; Kang-Hyun Kim; Jisun Lim; You-Sun Kim; Jinbeom Heo; Jongjin Choi; Jaeho Jeong; YongHwan Kim; Seong Who Kim; Yeon-Mok Oh; Myung-Soo Choo; Jaekyoung Son; Su Jung Kim; Hyun Ju Yoo; Wonil Oh; Soo Jin Choi; Sei Won Lee; Dong-Myung Shin
Journal:  Stem Cells Dev       Date:  2015-04-09       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.